Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
BULLISH SIGNAL DETECTED · Alpha
██.█% Sign up free to reveal

Denali Therapeutics Inc. (DNLI) AI Forecast

Our AI ranks Denali Therapeutics Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

✓ Free account • ✓ 30-day free trial

$DNLI Bullish Signal Full forecast available
Sign Up Free

Denali Therapeutics Inc. (DNLI) Stock Forecast Sept. 21, 2026

Denali Therapeutics Inc. (DNLI) AI Stock Price Forecast & Investment Analysis

Denali Therapeutics Inc. Stock Price Chart and Technical Analysis

Loading chart...

Denali Therapeutics Inc. (DNLI) - Comprehensive Stock Analysis & Investment Research

Deep dive into Denali Therapeutics Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on September 21, 2026 (UTC)

Denali Therapeutics Inc. Investment Summary

When evaluating whether Denali Therapeutics Inc. (DNLI) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Denali Therapeutics Inc. (DNLI) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $3 billion, the company is a mid-cap stock that typically offers a balance between growth potential and established business operations.

Financial Performance Analysis

Our comprehensive financial analysis covers Denali Therapeutics Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Denali Therapeutics Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Denali Therapeutics Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Denali Therapeutics Inc.

Sign Up Free
Corporate Identity

Denali Therapeutics Inc. (Stock Symbol: DNLI) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Denali Therapeutics Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Denali Therapeutics Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Denali Therapeutics Inc....

Unlock Full Company Profile

Get complete details about Denali Therapeutics Inc.

Sign Up Free
Revenue & Growth Analysis
Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Denali Therapeutics Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Denali Therapeutics Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Denali Therapeutics Inc....

Unlock Financial Analysis

Get complete financial metrics for Denali Therapeutics Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Denali Therapeutics Inc.'s AI Price Forecast

Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

4537 Stocks in the out-of-sample test
73.7% Rebalance periods with a positive net return
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Denali Therapeutics Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a mid-cap company, it occupies an attractive position balancing growth potential with established operations. Mid-caps often represent the 'sweet spot' for investors seeking companies that have proven their business models but still have meaningful runway for expansion. These companies are large enough to have competitive advantages but nimble enough to adapt quickly to market changes.

Industry Competitive Landscape

Denali Therapeutics Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-437 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Financial Strength & Leverage

Current ratio of 8.37 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Denali Therapeutics Inc. (DNLI) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Denali Therapeutics Inc. stock analysis.

Deep dive into Denali Therapeutics Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Denali Therapeutics Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Denali Therapeutics Inc.:

P/B Ratio 3.92x
Market Cap $3.27B
EPS $-2.93
Book Value/Share $5.22
FCF/Share $-2.74
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Denali Therapeutics Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Denali Therapeutics Inc.: An ROE of -61.2% indicates room for improvement in shareholder value creation.

ROE -61.2%
ROA -44.2%
ROIC -50.8%
Operating Margin -15058.2%
Net Margin -14191.2%
EBT Margin -15058.2%
Tax Rate 0.0%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Denali Therapeutics Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Denali Therapeutics Inc.: A current ratio of 8.37 indicates strong liquidity.

Current Ratio 8.37x
Quick Ratio 8.32x
D/E Ratio 0.39x
Financial Leverage 1.39x
Working Capital $664M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Denali Therapeutics Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Denali Therapeutics Inc.: Free cash flow of $-437M indicates cash challenges that need attention.

Operating Cash Flow -$434M
Free Cash Flow -$437M
Capital Spending -$3M
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Denali Therapeutics Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Denali Therapeutics Inc.:

Understanding Financial Statement Data

What these metrics mean: Key figures from Denali Therapeutics Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Denali Therapeutics Inc.:

Income Statement
Operating Income -$542M
Net Income -$511M
R&D Expense $401M
Balance Sheet Highlights (USD millions)
Total Current Assets $754M (65.1% of assets)
Cash & Short-term Investments $202M (17.4% of assets)
Accounts Receivable $4M (0.3% of assets)
Inventory $4M (0.4% of assets)
Total Liabilities $323M (27.9% of assets)
Short-term Debt $78M (6.8% of assets)
Dividend & Shareholder Information
Shares Outstanding 160M

Latest Denali Therapeutics Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Denali Therapeutics Inc. (DNLI) stock price and investment outlook.

📰 Loading...

Where DNLI sits on the market map

Explore the map →

Denali Therapeutics Inc. Industry Peers - Biological Products, (No Diagnostic Substances)

Companies classified under the same SEC industry code as Denali Therapeutics Inc. (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Company Ticker Symbol 90-Day AI Forecast (Alpha) Market Cap (USD M) P/E Ratio P/B Ratio
DNLI ██% $3.27B x 3.9x
AMGN ██% $212.55B 24.3x 18.2x
GILD ██% $186.13B x 15.7x
MRNA ██% $61.50B x 9.1x
ARGX ██% $61.15B x x
RVMD ██% $40.93B x 15.7x
BIIB ██% $32.34B 23.6x 1.7x
BNTX ██% $24.78B x x
MESO ██% $19.62B x x
NBIX ██% $14.86B 21.1x 4.0x
EXEL ██% $14.18B x 7.7x
HALO ██% $12.76B 30.9x 88.9x
TECH ██% $11.35B 62.4x 5.4x
TWST ██% $10.47B x 23.5x
APGE ██% $10.22B x x
RGEN ██% $9.98B 240.3x 4.7x
KRYS ██% $9.97B 41.3x 7.3x
KYMR ██% $9.79B x 6.5x
QGEN ██% $9.40B x 2.5x
IBRX ██% $8.99B x x
PCVX ██% $8.65B x 3.1x
IMVT ██% $7.63B x 10.4x
CGON ██% $6.94B x 6.7x
SRRK ██% $5.68B x 22.4x
CRSP ██% $5.64B x 3.2x
IOVA ██% $4.64B x 6.3x
ADPT ██% $4.45B x 31.1x
RLAY ██% $4.13B x 4.6x
DBVT ██% $3.58B x 21.2x
TARS ██% $3.43B x 9.9x
BEAM ██% $2.61B x 2.4x
BCRX ██% $2.24B x x
SCNI ██% $2.16B x 275.4x
ADMA ██% $2.13B 12.6x 5.2x
KOD ██% $2.06B x 33.7x
RXRX ██% $2.05B x 2.2x
VCEL ██% $2.05B 84.6x 5.5x
ALVO ██% $1.83B x x
VIR ██% $1.79B x 1.8x
COAG ██% $1.77B x 3.9x
NVAX ██% $1.67B x x
IMCR ██% $1.65B x 3.9x
TSHA ██% $1.64B x 4.2x
CGEM ██% $1.37B x 4.3x
MGTX ██% $1.27B 16.1x 5.9x
VOR ██% $1.27B x x
MAZE ██% $1.25B x 2.8x
REPL ██% $1.23B x 11.7x
JATT ██% $1.17B x 6.0x
ODTX ██% $1.17B x 2.8x
IMTX ██% $1.16B x x
VALN ██% $1.14B x x
GLUE ██% $1.03B x 2.1x
SLDB ██% $955M x 2.6x
SANA ██% $928M x 6.0x
CADL ██% $858M x 6.8x
FDMT ██% $841M x 2.1x
AURA ██% $660M x 2.1x
ALLO ██% $584M x 1.3x
PRME ██% $566M x 14.2x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Denali Therapeutics Inc. Stock Forecast

How accurate are Denali Therapeutics Inc. stock predictions?

A per-ticker accuracy statistic for DNLI is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

What factors influence Denali Therapeutics Inc. stock price forecasts?

Our analysis considers Denali Therapeutics Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Denali Therapeutics Inc. a good investment in 2026?

Based on our AI analysis, Denali Therapeutics Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Denali Therapeutics Inc. forecasts updated?

Denali Therapeutics Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on September 21, 2026.

Want a simpler view of Denali Therapeutics Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...